Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
March 13, 2024 at 05:04 pm EDT
Share
Rafael Holdings, Inc. reported earnings results for the second quarter and six months ended January 31, 2024. For the second quarter, the company reported sales was USD 0.068 million compared to USD 0.07 million a year ago. Net income was USD 6.05 million compared to net loss of USD 3.25 million a year ago. Basic earnings per share from continuing operations was USD 0.26 compared to basic loss per share from continuing operations of USD 0.13 a year ago. Diluted earnings per share from continuing operations was USD 0.25 compared to diluted loss per share from continuing operations of USD 0.13 a year ago. Basic earnings per share was USD 0.26 compared to basic loss per share of USD 0.14 a year ago. Diluted earnings per share was USD 0.25 compared to diluted loss per share of USD 0.14 a year ago.
For the six months, sales was USD 0.136 million compared to USD 0.14 million a year ago. Net income was USD 2.41 million compared to net loss of USD 1.66 million a year ago. Basic earnings per share from continuing operations was USD 0.1 compared to basic loss per share from continuing operations of USD 0.36 a year ago. Diluted earnings per share from continuing operations was USD 0.1 compared to diluted loss per share from continuing operations of USD 0.36 a year ago. Basic earnings per share was USD 0.1 compared to basic loss per share of USD 0.07 a year ago. Diluted earnings per share was USD 0.1 compared to diluted loss per share of USD 0.07 a year ago.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.
RAFAEL HOLDINGS, INC. 
